We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
+73.6%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$288M
AUM Growth
–
Cap. Flow
+$245M
Cap. Flow %
85.06%
Top 10 Hldgs %
61.94%
Holding
31
New
31
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$23.2M
2
CLDX icon
Celldex Therapeutics
CLDX
+$18.7M
3
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$17.9M
4
FDMT icon
4D Molecular Therapeutics
FDMT
+$15.6M
5
GOSS icon
Gossamer Bio
GOSS
+$15.4M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 94.1%
2 Financials 1.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$31.4M 10.87%
+548,374
New +$23.2M
NBP
2
NovaBridge Biosciences American Depositary Shares
NBP
$205M
$21.4M 7.43%
+454,550
New +$17.9M
CLDX icon
3
Celldex Therapeutics
CLDX
$2.77B
$18.2M 6.32%
+1,041,398
New +$18.7M
CRIS icon
4
Curis
CRIS
$9.53M
$18M 6.25%
+5,500
New +$6.6M
FDMT icon
5
4D Molecular Therapeutics
FDMT
$526M
$15.7M 5.43%
+377,777
New +$15.6M
PMVP icon
6
PMV Pharmaceuticals
PMVP
$66.1M
$15.4M 5.33%
+250,000
New +$9.81M
ARVN icon
7
Arvinas
ARVN
$518M
$15.2M 5.26%
+178,500
New +$6.16M
GOSS icon
8
Gossamer Bio
GOSS
$66.5M
$15.1M 5.24%
+1,563,138
New +$15.4M
XLRN
9
DELISTED
Acceleron Pharma
XLRN
$14.4M 4.98%
+112,363
New +$13.2M
CCXI
10
DELISTED
ChemoCentryx, Inc.
CCXI
$13.9M 4.83%
+225,076
New +$12.9M
CRDF icon
11
Cardiff Oncology
CRDF
$64.3M
$11.7M 4.05%
+650,000
New +$11.4M
RNAM
12
DELISTED
Avidity Biosciences
RNAM
$11M 3.8%
+430,041
New +$12.5M
DYN icon
13
Dyne Therapeutics
DYN
$4.04B
$10.1M 3.51%
+481,538
New +$9.52M
TSHA icon
14
Taysha Gene Therapies
TSHA
$1.59B
$8.5M 2.95%
+320,440
New +$6.9M
RCUS icon
15
Arcus Biosciences
RCUS
$3.57B
$7.79M 2.7%
+300,000
New +$7.26M
CALT
16
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$6.72M 2.33%
+200,000
New +$6.09M
KYNB
17
Kyntra Bio
KYNB
$28.5M
$5.42M 1.88%
+5,841
New +$6.14M
KNSA icon
18
Kiniksa Pharmaceuticals
KNSA
$4.83B
$5.22M 1.81%
+295,238
New +$5.19M
RVMD icon
19
Revolution Medicines
RVMD
$40.2B
$4.99M 1.73%
+126,136
New +$4.99M
KURA icon
20
Kura Oncology
KURA
$922M
$4.9M 1.7%
+150,000
New +$5.27M
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.7M 1.63%
+680,036
New +$4.35M
MLTX icon
22
MoonLake Immunotherapeutics
MLTX
$1.59B
$4.55M 1.58%
+400,000
New +$4.25M
KRON
23
DELISTED
Kronos Bio
KRON
$4.37M 1.51%
+146,173
New +$4.59M
JYAC
24
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$3.09M 1.07%
+300,000
New +$3.05M
VIE
25
DELISTED
Viela Bio, Inc. Common Stock
VIE
$3.07M 1.06%
+85,409
New +$2.99M
1
2

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for Octagon Capital Advisors, which disclosed 31 positions worth $288M. Its ten largest holdings account for 62% of the portfolio.

Its largest position is Apellis Pharmaceuticals: 548,374 shares worth $31.4M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, followed by Financials.

  • Octagon Capital Advisors's largest Q4 2020 buy was Apellis Pharmaceuticals: 548,374 shares worth $31.4M.
  • Octagon Capital Advisors's ten largest holdings make up 62% of its $288M portfolio in Q4 2020.
  • Octagon Capital Advisors disclosed 31 positions in Q4 2020, its first 13F filing on record.

Based on Octagon Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.